Treatment With Indapamide in Patients With Post-Surgical Hypoparathyroidism
NCT ID: NCT07034677
Last Updated: 2025-08-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
24 participants
INTERVENTIONAL
2025-08-31
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of Alendronate After Cure of Primary Hyperparathyroidism
NCT00359385
Randomized Study of Human Parathyroid Hormone in Middle-Aged Men With Idiopathic Osteoporosis
NCT00004406
Effect of Full Length Parathyroid Hormone, PTH(1-84) or Strontium Ranelate on Bone Markers in Postmenopausal Women With Primary Osteoporosis (FP-006-IM)
NCT00479037
Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.
NCT03027557
Use of NPSP558 in the Treatment of Hypoparathyroidism
NCT00732615
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients will do weekly blood sampling and 24 hour urine collection every second week.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Indapamide
14 days with active drug Indapamide 1.5 mg/day
Indapamide 1.5 MG SR
14 days treatment with indapamide 1.5 mg/day compared to placebo
Placebo
14 days with placebo
Placebo
14 days treatment with placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Indapamide 1.5 MG SR
14 days treatment with indapamide 1.5 mg/day compared to placebo
Placebo
14 days treatment with placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age ≥ 18 years
3. Require treatment with active vitamin D ≥ 1 µg/day
4. Ionized plasma calcium between 1.15-1.25 mmol/L
5. 25(OH)D vitamin ≥ 50 nmol/L
6. Plasma magnesium \> 0.65 mmol/L
7. Able to read and understand Danish
8. Willing and able to sign the informed consent form
Exclusion Criteria
2. Active cancer or former (except thyroid and basal cell skin) cancer treatment \< 1 year ago
3. Pregnancy, pregnancy plans, or breastfeeding \< 1 year ago
4. Abnormal arterial pressure at time of screening defined as symptomatic hypotension or systolic blood pressure \< 100 mmHg
5. Plasma potassium \< 3.5 mmol/L
6. Any current disease that might affect the calcium metabolism such as but not limited to:
1. Recent prolonged immobility
2. Untreated diabetes (HbA1c \> 53 mmol/mol)
3. Severe liver disease or hepatic encephalopathy
4. Untreated thyroid disease
7. Current disease that might affect gastrointestinal absorption
8. Use of medications such as lithium or diuretics within 4 weeks prior to start of treatment
9. Known allergy or sensitivity to Indapamide, its excipients or sulfonamides
10. Known galactosemia, lactase deficiency, or glucose-galactose malabsorption
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lars Rejnmark
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lars Rejnmark
MD, Ph.D., DMSc, prof
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Endocrinology and Internal Medicine
Aarhus, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-516000-41-01
Identifier Type: CTIS
Identifier Source: secondary_id
CTIS 2024-516000-41-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.